Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics (Nasdaq: DYN) announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN) announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website and a replay will be accessible for 30 days.
Details
News Market Reaction – DYN
On Jan 7, the day this news came out, DYN closed 7.01% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Current price
- $18.12
- Prior close before conference announcement
- 52-week range
- $6.36–$26.18
- 52-week low and high for DYN
- Q3 2025 cash
- $573.6M
- Cash and cash equivalents as of Q3 2025 10-Q
- Q3 2025 marketable securities
- $218.3M
- Marketable securities per Q3 2025 10-Q
- Q3 2025 net loss
- $108.0M
- Net loss, quarter ended Sep 30, 2025
- Q3 2025 EPS
- $0.76 loss per share
- Q3 2025 10-Q
- Dec 11 2025 gross proceeds
- $402.5M
- Gross proceeds from upsized common stock offering closing
- Shares in Dec 11 2025 offering
- 21,827,549 shares at $18.44
- Common stock sold in upsized offering
Historical Context
-
New director with commercialization and large acquisition integration experience.
-
Closing of upsized common stock offering with full underwriter option exercise.
-
Pricing of upsized $350M underwritten common stock offering at set share price.
-
Announcement of proposed $300M common stock offering with underwriter option.
-
Positive topline Phase 1/2 DELIVER trial results for z-rostudirsen in DMD.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.